Literature DB >> 17786988

Removal of cysteinylation from an unpaired sulfhydryl in the variable region of a recombinant monoclonal IgG1 antibody improves homogeneity, stability, and biological activity.

Douglas D Banks1, Himanshu S Gadgil, Gary D Pipes, Pavel V Bondarenko, Vipa Hobbs, Joanna L Scavezze, Jun Kim, Xu-Rong Jiang, Venkat Mukku, Thomas M Dillon.   

Abstract

The antibody MAB007 was recently shown to be cysteinylated on an unpaired cysteine residue in the CDR3 variable region. Cysteinylation at this position was not complete and resulted in heterogeneous lots of MAB007 with respect to this posttranslational modification. In this report, a mild redox step was used that effectively removed cysteinylation while keeping native inter and intra-molecular disulfide bonds intact. Biophysical methods were employed to determine what consequences cysteinylation of the variable region had by directly comparing cysteinylated and de-cysteinylated MAB007 antibodies. No differences were detected in secondary structure; however, several pieces of evidence indicated that cysteinylation may result in tertiary or quaternary structural perturbations. These included differences in the cation-exchange chromatography and fluorescence-emission spectra of the cysteinylated and de-cysteinylated antibodies as well as differences in the solvent accessibility of the unpaired cysteine residue determined by labeling experiments. Such structural changes induced by cysteinylation were shown to increase the rate of MAB007 aggregation and to decrease the melting temperature of the Fab region by as much as 6 degrees C. The bioactivity of MAB007 was also shown to be adversely affected by cysteinylation and a direct correlation was made between the percent cysteinylation and biological activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17786988     DOI: 10.1002/jps.21014

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  20 in total

Review 1.  Stability of IgG isotypes in serum.

Authors:  Ivan R Correia
Journal:  MAbs       Date:  2010-05-16       Impact factor: 5.857

Review 2.  Engineering the variable region of therapeutic IgG antibodies.

Authors:  Tomoyuki Igawa; Hiroyuki Tsunoda; Taichi Kuramochi; Zenjiro Sampei; Shinya Ishii; Kunihiro Hattori
Journal:  MAbs       Date:  2011-05-01       Impact factor: 5.857

Review 3.  Structure, heterogeneity and developability assessment of therapeutic antibodies.

Authors:  Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-12-17       Impact factor: 5.857

Review 4.  Chromatographic analysis of the acidic and basic species of recombinant monoclonal antibodies.

Authors:  Yi Du; Alison Walsh; Robin Ehrick; Wei Xu; Kimberly May; Hongcheng Liu
Journal:  MAbs       Date:  2012-07-23       Impact factor: 5.857

5.  Cysteinylation of a monoclonal antibody leads to its inactivation.

Authors:  Troy McSherry; Jennifer McSherry; Panfilo Ozaeta; Kenton Longenecker; Carol Ramsay; Jeffrey Fishpaugh; Steven Allen
Journal:  MAbs       Date:  2016-04-06       Impact factor: 5.857

Review 6.  Analytical comparability study of recombinant monoclonal antibody therapeutics.

Authors:  Alexandre Ambrogelly; Stephen Gozo; Amit Katiyar; Shara Dellatore; Yune Kune; Ram Bhat; Joanne Sun; Ning Li; Dongdong Wang; Christine Nowak; Alyssa Neill; Gomathinayagam Ponniah; Cory King; Bruce Mason; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-03-20       Impact factor: 5.857

7.  The impact of trisulfide modification of antibodies on the properties of antibody-drug conjugates manufactured using thiol chemistry.

Authors:  Renpeng Liu; Xuan Chen; Junia Dushime; Megan Bogalhas; Alexandru C Lazar; Thomas Ryll; Lintao Wang
Journal:  MAbs       Date:  2017-01-31       Impact factor: 5.857

8.  Structural and functional characterization of disulfide isoforms of the human IgG2 subclass.

Authors:  Thomas M Dillon; Margaret Speed Ricci; Chris Vezina; Gregory C Flynn; Yaoqing Diana Liu; Douglas S Rehder; Matthew Plant; Brad Henkle; Yu Li; Songpon Deechongkit; Brian Varnum; Jette Wypych; Alain Balland; Pavel V Bondarenko
Journal:  J Biol Chem       Date:  2008-03-12       Impact factor: 5.157

9.  Charge-based analysis of antibodies with engineered cysteines: from multiple peaks to a single main peak.

Authors:  Xiaoying Nancy Chen; Mary Nguyen; Fred Jacobson; Jun Ouyang
Journal:  MAbs       Date:  2009-11-12       Impact factor: 5.857

10.  Differential Inhibition of Nav1.7 and Neuropathic Pain by Hybridoma-Produced and Recombinant Monoclonal Antibodies that Target Nav1.7 : Differential activities of Nav1.7-targeting monoclonal antibodies.

Authors:  Sangsu Bang; Jiho Yoo; Xingrui Gong; Di Liu; Qingjian Han; Xin Luo; Wonseok Chang; Gang Chen; Sang-Taek Im; Yong Ho Kim; Judith A Strong; Ma-Zhong Zhang; Jun-Ming Zhang; Seok-Yong Lee; Ru-Rong Ji
Journal:  Neurosci Bull       Date:  2018-01-15       Impact factor: 5.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.